research: BRCA-Negative Ovarian Cancer Responds to Monotherapy With PARP Inhibitor | Cancer Survivors Network

Note: detailed article on PARP's/BRCA "....Interest in PARP inhibition was perhaps best reflected by the question an attendee at the packed session put to Dr. Gelmon.

"My problem is, as a practicing oncologist, I see these great, wonderful results, in a very difficult population of patients with ovarian cancer," he said. "I want to know when I can get my hands on some. There are patients dying today because of this lack of access.""